Nanotechnological strategies for the treatment of neglected diseases

Current Pharmaceutical Design

Volumn 19, Issue 41, 2013, Pages 7316-7329

  Khalil, Najeh Maissar ^a   de Mattos, Ana Cristina ^a   Carraro, Talita Cristina Moraes Moreira ^a   Ludwig, Daniel Brustolin ^a   Mainardes, Rubiana Mara ^a  

^a UNIVERSIDADE ESTADUAL DO CENTRO OESTE   (Brazil)

Author keywords

Chagas disease; Leishmaniasis; Liposomes; Malaria; Nanoparticles; Schistosomiasis

Indexed keywords

ANTICHAGASIC AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; ANTIPROTOZOAL AGENT; ANTITRYPANOSOMAL AGENT; DRUG CARRIER; LIPOSOME; NANOPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

CHAGAS DISEASE; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG TARGETING; EMULSION; HUMAN; LEISHMANIASIS; LIPOSOMAL DELIVERY; MALARIA; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; NEGLECTED DISEASE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; TUMOR MICROENVIRONMENT; WORLD HEALTH ORGANIZATION; ANIMAL; DRUG EFFECTS; LEISHMANIA; METABOLISM; NEGLECTED DISEASES; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTIMALARIALS; DRUG CARRIERS; HUMANS; LEISHMANIA; NANOPARTICLES; NANOTECHNOLOGY; NEGLECTED DISEASES; TREATMENT OUTCOME;

EID: 84890942172     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161281941131219135458     Document Type: Review

References (142)

1. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the "bottom billion" through control of neglected tropical diseases. Lancet 2009; 373: 1570-5.
2. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich SS, Sachs JD, Savioli L. Control of neglected tropical diseases. N Engl J Med 2007; 357: 1018-27.
3. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 505-21.
4. Romero EL, Morilla MJ. Nanotechnological approaches against Chagas disease. Adv Drug Deliv Rev 2005; 62: 576-88.
5. Santos-Magalhães NS, Mosqueira VCF. Nanotechnology applied to the treatment of malaria. Adv Drug Deliver Rev 2010; 62: 560-75.
6. Barratt, GM. Therapeutic applications of colloidal drug carriers. Pharm Sci Technol Today 2000; 3: 163-71.
7. Vauthier C, Couvreur P. Nanomedicines: a new approach for the treatment of serious diseases. J Biomed Nanotechnol 2007; 3: 223-34.
8. Forrest ML, Kwon GS. Clinical developments in drug delivery nanotechnology, Adv Drug Deliv Rev 2008: 60; 861-62.
9. Lopes R, Eleutério CV, Gonçalves LMD, Cruz MEM, Almeida AJ. Lipid nanoparticles containing oryzalin for the treatment of leishmaniasis. Eur J Pharm Sci 2012; 45: 442-50.
10. Postigo, JAR. Leishmaniasis in the World Health Organization Eastern Mediterranean Region. Int J Antimicrob Agents 2010; 36: 62-5.
11. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL. Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol 2012; 2: 11-9.
12. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010; 14: 1032-39.
13. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV. Recent advances in leishmaniasis treatment. Int J Infect Dis 2011; 15: 525-32.
14. Working to overcome the global impact of neglected tropical diseases - Summary. [Article in English, French]. Wkly Epidemiol Rec 2011; 86(13): 113-20.
15. Leishmaniasis: worldwide epidemiological and drug access update. World Health Organization, WHO [homepage in the Internet] [updated 2012 May; cited 2012, Jun]. Available from: http://www.who.int/vaccine_research/diseases/soa_parasitic/en/index3.html
16. Leishmaniasis and HIV coinfection. World Health Organization, WHO [homepage in the Internet] [updated 2012 May; cited 2012, Dec]. Available from: http://www.who.int/leishmaniasis/burden/hiv_coinfection/burden_hiv_coinfection/en/
17. Croft S, Barrett M, Urbina J. Chemotherapy of trypanosomiasis and leishmaniasis. Trends Parasitol 2005; 21: 508-12.
18. Croft S, Coombs G. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19: 502-08.
19. Sindermann H, Engel J. Development of miltefosine as an oral treatment for leishmaniasis. T Roy Soc Trop Med Hyg 2006; 100: 17-20.
20. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-40.
21. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. In-jectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-81.
22. Chagas, C. Nova entidade morbida do homen. Resumo geral dos estudos etiológicos e clínicos. Mem Inst Oswaldo Cruz 1911; 3: 219-75.
23. Salvatella R. Organizacion panamericana de la salud. Estimacioncuantitativa de la enfermedad de chagas en las Americas. Bol Oficina Sanit Panam 1984; 97(2): 159-65.
24. Carabarin-Lima A, González-Vázquez MC, Rodríguez-Morales O, Baylón-Pacheco L, Rosales-Encina JL, Reyes-López PA, Arce-Fonseca M. Chagas disease (American trypanosomiasis) in Mexico: an update. Acta Trop 2013; 127(2): 126-35.
25. Rassi A Jr., Rassi A, de Rezende JM. American Trypanosomiasis (Chagas Disease) Review Article. Infectious Disease Clinics of North America 2012; 26: 275-91.
26. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007; 298: 2171-81.
27. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375: 1388-402.
28. Carod-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neu-rol 2010; 9: 533-42.
29. Urbina JA, DoCampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003; 19: 495-501.
30. Blanchard TJ, Milne LM, Pollock R, Cook GC. Early chemotherapy of imported neuroschistosomiasis. Lancet 1993; 341: 959.
31. Schistosomiasis. Fast Sheet no 115. World Health Organization, WHO [homepage in the Internet] [cited 2012]. Available from: http://www.who.int/mediacentre/factsheets/fs115/en/.
32. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomia-sis. Lancet 2006; 308: 1106-18.
33. Utzinger J, Ngoran EK, Caffrey CR, Keiser J. From innovation to application: Social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 2011; 120: 121-37.
34. Davis A. Schistosomiasis, In: Cook GC, Zumla AI (Eds), Mansońs Tropical diseases, Saunders Elsevier 2009; 1425-60.
35. Lambertucci JR, Silva LCS, Andrade LM, et al. Imaging techniques in the evaluation of morbidity in schistosomiasis mansoni. Acta Trop 2008; 108: 209-17.
36. Muth S, Sayasone S, Odermatt-Biays S, Phompida S, Duong S, Odermatt P. Schistosoma mekongi in Cambodia and Lao People's Democratic Republic. Adv Parasitol 2010; 72: 179-203.
37. Wahl SM, Frazier-Jessen M, Jin WW, Kopp JB, Sher A, Cheever AW. Cytokine regulation of schistosome-induced granuloma and fibrosi. Kidney Int 1997; 5: 1370-5.
38. Ferrari TCA. Involvement of Central Nervous System in the Schistosomiasis. Mem Inst Oswaldo Cruz, 2004; 99: 59-62.
39. Sabadini PLP, Dias LCS. Altered response of Strain of Schistosoma mansoni to oxamniquine and praziquantel. Mem Inst Oswaldo Cruz 2002; 97: 381-5.
40. Melo AL, Barcellos NMS, Demicheli C, Frézard F. Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. Int J Pharm 2003; 255: 227-30.
41. Liang YS, Coles GC, Doenhoff MJ, Southgate VR. In vitro responses of praziquantel-resistant and susceptible Schistosoma mansoni to praziquantel. Int J Parasit 2001; 31: 1227-35.
42. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61: 294-303.
43. Becket G, Schep LJ, Tan MY. Improvement of the in vitro dissolution of praziquantel by complexation with a-,(3- and y-ciclodextrins. Int J Pharm 1999; 179: 65-71
44. Doenhoff MJ, Chiodini PL, Hamilton JV. Specific and sensitive diagnosis of schistosome infection: can it be done with antibodies? Trends Parasitol 2004; 20: 35-9.
45. Rollinson D, Knopp S, Levitz S, et al. Time to set the agenda for schistosomiasis elimination. Acta Trop 2012 DOI 10.1016/j.actatropica.2012.04.013.
46. World Malaria Report 2011. World Health Organization, WHO [homepage in the Internet] [cited 2011]. Available from: http://www.who.int/malaria/world_malaria_report_2011/9789241564403_eng.pdf
47. Wernsdorfer WH, McGregor I, editors. Malaria: principles and practice of malariology. Edinburg: Churchill Livingstone; 1988.
48. Laishram DD, Sutton PL, Nanda N, et al. The complexities of malaria disease manifestations with a focus on asymptomatic malaria. Malaria J 2012, 11: 1-15.
49. Murambiwa P, Masola B, Govender T, Mukaratirwa S, Musabayane CT.Anti-malarial drug formulations and novel delivery systems: A review. Acta Trop 2011; 118: 71-9.
50. Alkadi HO. Antimalarial drug toxicity: A review. Chemother 2007; 53: 385-91.
51. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 2004; 7: 257-66.
52. Sharma A, Sharma US. Liposomes in drug delivery: Progress and limitations. Int J Pharm 1997; 154: 123-40.
53. Alving CR, Steck EA, Hanson WL, Loizeaux OS, Chapman Jr WL, Waits VB. Improved therapy of experimental leishmaniasis by use of a liposome encapsulated antimonial drug. Life Sci 1978; 22: 1021-5.
54. Alving CR, Steck EA, Hanson WL, et al. Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines and tetracycline. Life Sci 1980; 26: 2231-8.
55. Alving CR, Swartz G, Hendricks LD, Chapman Jr WL, Waits VB, Hanson WL. Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. Ann Trop Med Parasit 1984; 78: 279-86.
56. Chapman Jr WL, Hanson WL, Alving CR, Hendricks LD. An-tileishmanial activity of liposome-encapsulated meglumine anti-monate in the dog. Am J Vet Res 1984; 45: 1028-30.
57. Gangneux JP, Sulahian A, Garin YJ, Farinotti R, Derouin F. Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob Agents Chemother 1996; 40: 1214-8.
58. Yardley V, Croft SL. Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis. Antimicrob Agents Chemother 1997; 41: 752-6.
59. Di Martino L, Davidson RN, Giacchino R, et al. Treatment of visceral leishmaniasis in children with liposomal amphotericin B. J Pediatr 1997; 131: 271-7.
60. Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of pediatric visceral leishmaniasis: ampho-tericin B or pentavalent antimony compounds? Int J Antimicrob Agents 2005; 25: 26-30.
61. Croft SL, Davidson RN, Thornton EA. Liposomal amphotericin B in the treatment of visceral leishmaniasis. J Antimicrob Chemother 1991; 28: 111-8.
62. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal ampho-tericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319-22.
63. Berman JD, Badaro R, Thakur CP, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76: 25-32.
64. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomized trial. B M J 2001; 323: 419-22.
65. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicentre study. Am J Trop Med Hyg 2002; 66: 143-6.
66. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicentre study. Clin Infect Dis 2003; 37: 800-4.
67. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38: 377-83.
68. Sundar S, Chakravarty J. Liposomal Amphotericin B and Leishma-niasis: Dose and Response. J Glob Infect Dis. 2010; 2: 159-66.
69. Balasegaram M, Ritmeijer K, Lima MA, et al. Liposomal ampho-tericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs 2012; 17: 493-510.
70. Solomon M, Pavlotzky F, Barzilai A, Schwartz E. Liposomal am-photericin B in comparison to sodium stibogluconate for Leishma-nia braziliensis cutaneous leishmaniasis in travelers. J Am Acad Dermatol. 2012
71. Ritmeijer K, Ter Horst R, Chane S, et al. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clin Infect Dis. 2011; 53: 152-8.
72. Amato VS, Tuon FF, Camargo RA, Souza RM, Santos CR, Nicodemo AC. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg 2011; 85: 818-9.
73. Sundar S, Sinha PK, Verma DK, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg 2011; 105: 115-7.
74. Sinha PK, Roddy P, Palma PP, et al. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg. 2010; 83: 357-64.
75. Solomon M, Pavlotsky F, Leshem E, Ephros M, Trau H, Schwartz E. Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica. J Eur Acad Dermatol Venereol 2011; 25: 973-7.
76. Sarkar S, Mandal S, Sinha J, Mukhopadhyay S, Das N, Basu M. Quercetin: critical evaluation as an antileishmanial agent in vivo in hamsters using different vesicular delivery modes. J Drug Target 2002; 10: 573-8.
77. Cauchetier E, Paul M, Rivollet D, Fessi H, Astier A, Deniau M. Therapeutic evaluation of free and liposome-encapsulated atova-quone in the treatment of murine leishmaniasis. Int J Parasitol 2000; 30: 777-83.
78. Croft SL, Engel J. Miltefosine - discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg 2006; 100: 4-8.
79. Papagiannaros A, Bories C, Demetzos C, Loiseau P. Antileishma-nial and trypanocidal activities of new miltefosine liposomal formulations. Biomed Pharmacother 2005; 59: 545-50.
80. Montanari J, Maidana C, Esteva MI, Salomon C, Morilla MJ, Romero EL. Sunlight triggered photodynamic ultradeformable liposomes against Leishmania braziliensis are also leishmanicidal in the dark. J Control Release 2010; 147: 368-76.
81. Owais M, Gupta CM. Targeted drug delivery to macrophages in parasitic infections. Curr Drug Deliv 2005; 2: 311-8.
82. Pal S, Ravindran R, Ali N. Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in Balb/c mice. Antimicrob Agents Chemother 2004; 48: 3591-93.
83. Agrawal A, Gupta C. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv Drug Deliv Rev 2000; 41: 135-46.
84. Mazumder S, Ravindran R, Banerjee A, Ali N. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with leishmanial antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine 2007; 25: 8771-81.
85. Nagill R, Kaur S. Vaccine candidates for leishmaniasis: A review. Int Immunopharmacol 2011; 11: 1464-88.
86. Mainardes RM, Gremião MPD, Brunetti IL, Da Fonseca LM, Khalil NM. Zidovudine-loaded PLA and PLA-PEG blend nanopar-ticles: Influence of polymer type on phagocytic uptake by polymorphonuclear cells. J Pharm Sci 2009; 98: 257-267.
87. Khalil NM, Carraro E, Cótica LF, Mainardes RM. Potential of polymeric nanoparticles in AIDS treatment and prevention. Expert Opin Drug Deliv 2011; 8: 95-112.
88. Mainardes RM, Khalil NM, Gremião MP. Intranasal delivery of zidovudine by PLA and PLA-PEG blend nanoparticles. Int J Pharm 2010; 395: 266-71.
89. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001; 70: 1-20.
90. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mat Sci 2002; 6: 319-27.
91. Essa S, Rabanel JM, Hildgen P. Effect of polyethylene glycol (PEG) chain organization on the physicochemical properties of poly (D, L-lactide) (PLA) based nanoparticles. Eur J Pharm Bio-pharm 2010; 75: 96-106.
92. Gaspar R, Opperdoes FR, Préat V, Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of prima-quine-loaded nanoparticles against intracellular Leishmania donovani. Ann Trop Med Parasit 1992; 86: 41-9.
93. Espuelas MS, Legrand P, Loiseau PM, Bories C, Barrat G, Irache JM. In vitro antileishmanial activity of amphotericin B loaded in poly(e- caprolactone) nanospheres. J Drug Target 2002; 10: 593-99.
94. Van de Ven H, Vermeerschb M, Matheeussenb A, et al. PLGA nanoparticles loaded with the antileishmanial saponin ß-aescin: Factor influence study and in vitro efficacy evaluation. Int J Pharm 2011; 420: 122-32.
95. Torres-Santos E, Rodrigues Jr J, Moreira D, Kaplan M, Rossi-Bergmann B. Improvement of in vitro and in vivo antileishmanial activities of 2',6'-dihydroxy-4'-methoxychalcone by entrapment in poly (D,L lactide) nanoparticles. Antimicrob Agents Chemother 1999; 43: 1776-8.
96. Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 2009; 71: 161-72
97. Müller-Goymann CC. Physicochemical characterization of colloidal drug delivery systems such as reverse micelles, vesicles, liquid crystals and nanoparticles for topical administration. Eur J Pharm Biopharm 2004; 58: 343-56.
98. Doroud D, Zahedifard F, Vatanara A, et al. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. J Control Release 2011; 153: 154-62.
99. Kao HP, Abney JR, Verkmann AS. Determinants of the transla-tional mobility of a small solute in cell cytoplasm. J Cell Biol 1993; 120: 175-84.
100. Belting M, Sandgren S, Wittrup A. Nuclear delivery of macro-molecules: barriers and carriers. Adv Drug Deliv Rev 2005; 57: 505-27.
101. Prokop A, Davidson JM. Nanovehicular intracellular delivery systems. J Pharm Sci 2008; 97: 3518-90.
102. Yoshihara E, Tachaban H, Nakae T. Trypanocidal activity of the stearylamine-bearing liposome. Life Sci 1987; 40: 2153-59.
103. Morilla MJ, Montanari JA, Prieto MJ, Lopez MO, Petray PB, Romero EL. Intravenous liposomal benznidazole as trypanocidal agent: increasing drug delivery to liver is not enough. Int J Pharm 2004; 278: 311-8.
104. Lamas MC, Villagi L, Nocito I, et al. Development of parenteral formulations and evalutions of the biological activity of the try-panocide drug benznidazole. Int J Pharm 2006; 307: 239-43.
105. Lutwyche P, Cordeiro C, Wiseman D, et al. Finlay, Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 1998; 42: 2511-20.
106. Morilla MJ, Montanari JA, Frank F, et al. Etanidazole in pH-sensitive liposomes: design, characterization, and in vitro/in vivo anti-Trypanosoma cruzi activity. J Control Release 2005; 103: 599-607.
107. Gonzalez-Martin G, Merino I, Rodriguez-Cabezas MN, Torres M, Nuñez R, Osuna A. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcya-noacrylates. J Pharm Pharmacol 1998; 50: 29-35.
108. González-Martin G, Figueroa C, Merino I, Osuna A. Allopurinol encapsulated in polycyanoacrylate nanoparticles as potential lysosomatropic carrier: preparation and trypanocidal activity. Eur J Pharm Biopharm 2000; 49: 137-42.
109. Sánchez G, Cuellar D, Zulantay I, Gajardo M, González-Martin G. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol Res 2002; 35: 39-45.
110. Molina J, Urbina J, Gref R, Brener Z, Maciel-Rodrigues J Jr. Cure of experimental Chagas' disease by the bis-triazole DO870 incorporated into 'stealth' polyethyleneglycol-polylactide nanospheres. J Antimicrob Chemother 2001; 47: 101-4.
111. Flaig RM, Rosenkranz V, Wink M, Fricker G. Ktenate nanoparti-cles (bdellosomes): a novel strategy for delivering drugs to parasites or tumours. J Drug Deliv Sci Technol 2005; 15: 59-63.
112. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquantel: effect of formulation variables on size distribution. Int J Pharm 2005; 290: 137-44.
113. Mainardes RM, Evangelista RC. Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul 2005; 22: 13-24.
114. Gagliardi M, Bardi G, Bifone A. Polymeric nanocarriers for controlled and enhanced delivery of therapeutic agents to the CNS. Ther Deliv. 2012; 3: 875-87.
115. Frézard F, Melo AL. Evaluation of the schistomicidal efficacy of lipossome-entrapped oxamniquine. J Inst Med Trop São Paulo 1997; 39: 91-100.
116. Mourão SC, Costa PI, Salgado HRN, Gremião MPD. Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int J Pharm 2005; 295: 157-62.
117. Frezza TF, Madi RR, Banin TM, et al. Effect of praziquantel in liposomes on Schistosoma mansoni eggs at different development stages. Rev Ciênc Farm Básica 2007; 29: 209-14.
118. Li Y, Yehui G, Hao L, Yu Z, Jinsong Y, Yanyan C. Enhancement the oral biovailability of praziquantel by incorporation into solid lipid nanoparticles. Int J Pharm Sci 2009; 64: 86-9.
119. Araújo SC, Mattos ACA, Teixeira HF, Coelho PMZ, Nelson DL, Oliveira MC. Improvement of in vitro efficacy of a novel schis-tosomicidal drug by incorporation into nanoemulsions. Int J Pharm 2007; 337: 307-15.
120. Parween S, Gupta PK, Chauhan VS. Induction of humoral immune response against PfMSP-119 and PvMSP-119 using gold nanopar-ticles along with alum. Vaccine 2011; 29: 2451-60.
121. Rajakumar G, Rahuman AA. Larvicidal activity of synthesized silver nanoparticles using Eclipta prostrata leaf extract against filariasis and malaria vectors. Acta Trop 2011; 118: 196-203.
122. Akhtar F, Rizvi MMA.; Kar SK. Oral delivery of curcumin bound to chitosan nanoparticles cured Plasmodium yoelii infected mice. Biotechnol Adv 2012; 30: 310-20.
123. Pirson P, Steiger RF, Trouet A. Liposomes in the chemotherapy of experimental murine malaria. T Roy Soc Trop Med H 1979; 73: 347.
124. Henriksen I, Vågen SR, Sande SA, Smistad G, Karlsen J. Interactions between liposomes and chitosan II: effect of selected parameters on aggregation and leakage. Int J Pharm 1997; 146: 193-204.
125. Stensrud G, Sande SA, Kristensen S, Smistad G. Formulation and characterisation of primaquine loaded liposomes prepared by a pH gradient using experimental design. Int J Pharm 2000; 198: 213-28.
126. Gabriëls M, Plaizier-Vercammen J. Physical and chemical evaluation of liposomes, containing artesunate. J Pharm Biomed Anal 2003; 31: 655-67.
127. Qiu L, Jing N, Jin Y. Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method. Int J Pharm 2008; 361: 56-63.
128. Pirson P, Steiger RF, Trouet A, Gillet J, Herman F. Primaquine liposomes in the chemotherapy of experimental murine malaria. Ann Trop Med Parasitol 1980; 74: 383-91.
129. Bayomi MA, Al-Angary AA, Al-Mehsal MA, Al-Dardiri MM. In vivo evaluation of arteether liposomes. Int J Pharm 1998; 175: 1-7.
130. Chimanuka B, Gabriëls M, Detaevernier MR, Plaizier-Vercammen JA. Preparation of p-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J Pharm Biomed Anal 2002; 28: 13-22.
131. Longmuir KJ, Robertson RT, Haynes SM, Baratta JL, Waring AJ. Effective targeting of liposomes to liver and hepatocytes in vivo by incorporation of a Plasmodium amino acid sequence. Pharm Res 2006; 23: 759-69.
132. Haynes SM, Longmuir KJ, Robertson RT, Baratta JL, Waring AJ. Liposomal polyethyleneglycol and polyethyleneglycol-peptide combinations for active targeting to liver in vivo. Drug Deliv 2008; 15: 207-17.
133. Owais M, Varshney GC, Choudhury A, Chandra S, Gupta CM. Chloroquine Encapsulated in Malaria-Infected Erythrocyte-Specific Antibody-Bearing Liposomes Effectively Controls Chloroquine-Resistant Plasmodium berghei Infections in Mice. Antimicrob Agents Chemother 1995; 39: 180-4.
134. Chandra S, Agrawal AK, Gupta CM. Chloroquine delivery to erythrocytes in Plasmodium berghei-infected mice using antibody-bearing liposomes as drug vehicles. J Biosci 1991; 16: 137-44.
135. Alving CR. Design and selection of vaccine adjuvants: animal models and human trials. Vaccine 2002; 20: 856-64.
136. Tyagi RK, Sharma SP, Vyas SP, Mehta A. Various carrier sys-tem(s) mediated genetic vaccination strategies against malaria. Expert Rev Vaccines 2008; 7: 499-520.
137. Mosqueira VCF, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. Efficacy and Pharmacokinetics of Intravenous Nano-capsule Formulations of Halofantrine in Plasmodium berghei-Infected Mice. Antimicrob Agents Chemother 2004; 48: 1222-8.
138. Nayak AP, Tiyaboonchai W, Patankar S, Madhusudhan B, Souto EB. Curcuminoids-loaded lipid nanoparticles: Novel approach towards malaria treatment. Colloids Surf B Biointerfaces 2010; 81: 263-73.
139. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol 2007; 59: 935-40.
140. Joshi M, Pathak S, Sharma S, Patravale V. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int J Pharm 2008; 362: 172-8.
141. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. N Engl J Med 2010; 362: 504-12.
142. Leishmaniasis - Access to medicines - Costs of medicines in current use for the treatment of leishmaniasis and HIV coinfection. World Health Organization, WHO [homepage in the Internet] [updated 2010; cited 2012, Dec]. Available from: http://www.who.int/leishmaniasis/research/978_92_4_12_949_6_Annex6.pdf